Reductions in sleep quality and circadian activity rhythmicity predict longitudinal changes in objective and subjective cognitive functioning in women treated for breast cancer

Sonia Ancoli-Israel1,2 · Lianqi Liu3 · Loki Natarajan2,4 · Michelle Rissling1 · Ariel B. Neikrug5 · Shawn D. Youngstedt6 · Paul J. Mills4 · Georgia R. Sadler2,7 · Joel E. Dimsdale1,2 · Barbara A. Parker2,3 · Barton W. Palmer1,8

Received: 13 May 2021 / Accepted: 3 December 2021 / Published online: 26 December 2021
© The Author(s) 2021

Abstract

Purpose  To examine long-term cognitive effects of chemotherapy and identify predictors among women with breast cancer (WBC).

Patients and methods  Sixty-nine WBC scheduled to receive chemotherapy, and 64 matched-controls with no cancer, participated. Objective and subjective cognition, total sleep time, nap time, circadian activity rhythms (CAR), sleep quality, fatigue, and depression were measured pre-chemotherapy (Baseline), end of cycle 4 (Cycle-4), and one-year post-chemotherapy (1-Year).

Results  WBC showed no change in objective cognitive measures from Baseline to Cycle-4 but significantly improved from both time points to 1-Year. Matched-controls showed an increase in test performance at all time points. WBC had significantly higher self-reported cognitive dysfunction at Cycle-4 and 1-Year compared to baseline and compared to matched-controls. Worse neuropsychological functioning was predicted by less robust CARs (i.e., inconsistent 24 h pattern), worse sleep quality, longer naps, and worse cognitive complaints. Worse subjective cognition was predicted by lower sleep quality and higher fatigue and depressed mood.

Conclusion  Objective testing showed increases in performance scores from pre- and post-chemotherapy to one year later in WBC, but matched-controls showed an increase in test performance from baseline to Cycle-4 and from Cycle-4 to 1-Year, likely due to a practice effect. The fact that WBC showed no practice effects may reflect a form of learning deficit. Compared with the matched-controls, WBC reported significant worsened cognitive function. In WBC, worse objective and subjective cognitive functioning were predicted by worse sleep and sleep-related behaviors (naps and CAR). Interventions that target sleep, circadian rhythms, and fatigue may benefit cognitive function in WBC.

Keywords  Cognitive function · Circadian activity rhythms · Sleep quality · Fatigue · Depression · Breast cancer · Chemotherapy
Introduction

Chemotherapy can produce reports of acute cognitive dysfunction [1–3] with one-third of patients with cancer reporting long-term impairment lasting up to five years or more [1, 3]. In addition, those receiving high-dose chemotherapy or concurrent cytotoxic agents have more cognitive disruption than those on standard doses [4, 5]. The deleterious cognitive effects, both objective and subjective, persist even after adjusting for variance attributable to depression, age, education, and premorbid IQ [6, 7]. While there is no specific cognitive profile characterizing the effects of chemotherapy, chemotherapy appears to affect multiple cognitive domains including attention/concentration and working memory, episodic learning and memory, mental processing/psychomotor speed, and executive function [8–10]. Although the cognitive decline may be subtle, it is common and can have a deleterious impact on quality of life (QOL) [1, 8, 11]. Imaging studies confirm that chemotherapy induces functional and/or structural changes in the brain which are associated with worse cognitive performance [12–14], providing fundamental evidence supporting these findings. Nevertheless, cognitive dysfunction is rarely diagnosed or addressed in patients with cancer.

A major question is whether there are modifiable predictors of cognitive dysfunction in patients with cancer. Being able to identify predictors could lead to preventive measures. Impairments in CARs have been linked with prospective cognitive decline in older adults [15], and worsening of CAR synchronization during chemotherapy for breast cancer is associated with reported declines in cognitive function [16]. Moreover, impairments in cognitive function have been linked with poor sleep in breast cancer [17, 18]. Our previous research with these same WBC revealed a wide range of circadian synchronization and a wide range of sleep [19]. Therefore, the current study explored whether decreases in robustness of CAR and sleep quality and increases in fatigue predict decreases in cognitive functioning, as these factors have been predictive of other outcomes in cancer, including survival [20], QOL [20, 21], and markers of cancer progression [22]. Consensus guidelines suggest that studies include baseline or pre-chemotherapy treatment assessments, longitudinal or long-term follow-up, and standardized use of measures [23]. Inclusion of subjective assessment of cognitive decline is also encouraged as it is associated with patient QOL [24] and possibly with treatment adherence. The present study addressed these issues by collecting data before, during and one-year after chemotherapy and by using objective and subjective assessments of cognition. Such longitudinal studies with pre-, post-chemotherapy, and subsequent follow-up measurements may elucidate whether the cognitive changes are preventable or reversible following the end of chemotherapy.

Our primary hypothesis was that cognitive performance will decrease from pre-chemotherapy to the fourth cycle of chemotherapy in WBC relative to matched-controls but will remain stable from cycle four to one-year follow-up. Our second hypothesis was that WBC experiencing worsening CAR, poor sleep, and fatigue (after controlling for depression) would exhibit decreases in cognitive function compared to baseline.

Methods

Participants

Women (n = 107) with newly diagnosed stage I-III BC scheduled to receive at least four cycles of adjuvant or neo-adjuvant chemotherapy were referred by oncologists in the San Diego area, primarily from the UC San Diego Moores Cancer Center. Each was screened for inclusion and 69 were enrolled in the study (see Fig. 1).

Each participant was asked to nominate a friend with no cancer for inclusion in the matched-control group. For those women with no adequately comparable friend or who did not wish to nominate a friend, a separate recruitment was performed to find demographically matched volunteers. Altogether, 121 women without a history of cancer were evaluated for inclusion in the control group based on closely matching to a specific cancer patient by age (within five years), ethnicity, and education. Sixty-four women with no cancer were included in this matched-control comparison group. Some data from participants in the present study were included in prior published reports [19, 25, 26]; however, the present report represents our first examination of the association of these measures with longitudinal cognitive tests.

Exclusion criteria included pregnancy, current bone marrow transplant, radiotherapy, metastatic breast cancer, confounding underlying medical illnesses, significant pre-existing anemia (Hg < 10 gm/dl), or other physical or psychological impairments. Exclusion criteria for the control group also included any history of cancer (other than melanoma skin cancers).

The study was approved by the UCSD Office of IRB Administration and by the UC San Diego Moores Cancer Center’s Protocol Review and Monitoring Committee. All women provided written informed consent before participation.
**Procedures**

After HIPAA-waiver authorization was provided, medical records were abstracted for medical history and current medication use. Data were collected at three time points: before the start of chemotherapy (Baseline), at the end of cycle 4 chemotherapy (Cycle-4), and 1 year after the start of chemotherapy (1-Year). At each time point, a neuropsychological test battery, along with other questionnaires, was administered. Starting on the first day of each time point, women also wore an actigraph for three consecutive days (72 h) and completed a daily sleep log used for editing actigraphy data.

**Measures**

**Cognitive functioning**

Objective cognitive functioning was examined with a neuropsychological test battery which included tests focusing on four domains of cognitive abilities suggested in prior literature as being the most sensitive to chemotherapy-related changes: (1) Episodic Learning/Memory, (2) Executive Function, (3) Verbal and Visual Attention/Working Memory, (4) Psychomotor/Mental Processing Speed [23]. The specific tests within each domain are shown in Table 1. In selecting the above battery, we endeavored to balance comprehensive assessment with participant burden [27]. In addition, where possible, we selected tests with multiple alternative forms (particularly HVLT-R and BVSM-R) to avoid practice effects from learned content over repeated testing. All tests were administered in the morning either at the participant’s home or at the clinic.

A summary measure of cognitive ability, a neuropsychological composite score, was computed as follows: each component raw test score was converted to a $z$-score by subtracting the baseline mean and dividing by the standard deviation. $Z$-scores were coded so that higher scores represented better functioning. The composite score was defined as the mean of $z$-scores over the entire battery.

Subjective cognitive functioning was assessed with the Patient’s Assessment of Own Functioning Inventory (PAOF) [28], a validated self-report questionnaire designed to elicit an individual’s ratings of her ability to function in everyday tasks. The 33-items cover areas of memory (Memory), language and communication (Language), sensory-perceptual and motor skills (Sensory-Motor), and higher level cognitive and intellectual function (Cognitive). The questions are rated on a 6-point scale from 0 (almost never) to 5 (almost always). A total score and scores for the four areas are calculated using Rourke’s method, with a higher score indicating more self-reported cognitive concerns [28]. Only total score results are presented.

**Sleep**

The Pittsburgh Sleep Quality Index (PSQI) [29] was used for subjective sleep quality. It measures reported sleep patterns and problems, including sleep quality, sleep latency, sleep efficiency, and napping behavior. The PSQI is a 19-item questionnaire that has been demonstrated to have high...
internal consistency (0.83), test-retest reliability (0.85), and diagnostic validity. The global score (range 0–21) reflects the overall quality of sleep over the prior one-week with high scores reflecting poor sleep quality.

Objective measures of sleep were obtained with wrist actigraphy. All women wore an actigraph for three consecutive days (72 h). The Actillume-II (Ambulatory Monitoring Inc, Ardsley, New York) and the Actiwatch-Light (Philips Respironics Mini Mitter, Bend, OR) were used. The Actillume-II is a small device approximately 1 × 3 × 6 cm in size, containing a piezoelectric linear accelerometer (sensitive to 0.003 g and above), a microprocessor, 32K RAM memory, and associated circuitry. The Actiwatch-Light is a watch-like device approximately 1 × 2.5 × 5 cm in size, also containing a piezoelectric linear accelerometer (sensitivity < .01 g-force) with a sampling rate of 32 Hz to measure and record wrist movement. Once collected, data were downloaded onto a desktop computer and information from a sleep log which recorded time to bed, time up in the morning, nap time was used for editing. The Action-4 software for Actillume-II and Actiware-5 software for Actiwatch-Light were used to score sleep and wake. A one-minute epoch setting was used for both devices. For the sleep/wake analysis, the SUMACT (summary activity) channel was used for Actillume, and the default (medium) activity sensitivity threshold was set for the Actiwatch-Light. The following parameters are reported in this study: total sleep time (TST), wake after sleep onset (WASO), percent sleep (%sleep), and total nap time (NAP-TIME). Percent sleep was defined as the amount of sleep between sleep onset and final awakening. This is similar to sleep efficiency except that the starting time point is sleep onset and not lights out (since lights out is less reliable with actigraphy) and so sleep onset latency is not included in the equation. A nap was defined as at least ten continuous minutes of inactivity (i.e., sleep) during the out-of-bed period.

As previously published [19, 25, 26], 13 WBC and 7 women with no history of cancer wore an Actillume-II, and the remainder wore an Actiwatch-Light. A validation study showed high correlation between the two (all r’s > 0.85), and therefore the data from the two devices were deemed equivalent.

For each participant, actigraphy began on the same day at each time point. The day chosen was based on the day of chemotherapy administration. While the ideal recording time for an actigraph is generally one week, due to potential subject burden, the minimum of three days suggested by the AASM practice parameters for actigraphy [30] was used in this study.

Circadian activity rhythms

The activity level per epoch (minute) measured by actigraphy was used to estimate CAR. A robust CAR would be indicated by a clear contrast between daytime and nighttime activity. This patient’s rhythm would remain stable and robust throughout chemotherapy. A disrupted rhythm would be one with lower amplitude and less contrast between daytime and nighttime activity as compared to a rhythm of good rhythmicity, in this case, the comparison to baseline (see Fig. 2). CARs were analyzed by fitting each subject’s activity data to a 5-parameter extended cosine model, an antilogistic transformation of the standard cosine curve, allowing for estimation of parameters describing the shape of the 24-h rest/activity rhythm [31]. A series of variables could be calculated from this model, including circadian activity rhythmicity (R-squared) [32]. R-squared is the reduction in squared error which results from using a model.

---

| Table 1 Domains and tests used for the neuropsychological test battery |
|--------------------------|--------------------------|--------------------------|
| Domain                   | Test                     | Score used for analysis  |
|----------------------------|----------------------------|--------------------------|
| Episodic Learning/Memory  | Hopkins Verbal Learning Test – Revised (HVLT-R); Published parallel forms for the HVLT-R were used in fixed-order to practice effects from item content familiarity. | Total recall on learning trials 1 through 3 |
| Executive Function        | 1. Trail Making Part B, 2. Wisconsin Card Sorting Test (WCST-64) 3. Color-Word Interference trial of the Stroop Color and Word Test 4. Letter Fluency (FAS) Test and Category (Animals) Fluency Test | 1. Seconds to complete 2. Conceptual level responses 3. Total words completed 4. Total correct words generated |
| Verbal and Visual Attention/Working Memory | 1. Digit Span of the Wechsler Adult Intelligence Scale - Third Edition (WAIS-III) 2. Digit Cancellation task | 1. Raw score 2. Total correct |
| Psychomotor/Mental Processing Speed | 3. Trail Making Test Part A 4. WAIS-III Digit Symbol and Symbol Search subtests 5. Stroop Color and Word Test | 3. Time to complete (seconds) 4. Raw scores 5. Total words completed on the Color or Word trial |
to summarize data (and predict future values) compared to the mean [32]. Data sets that are most rhythmic or have the strongest rhythm yield the largest R-squared. The R-squared is reported in the study as the measurement of circadian activity rhythmicity. Figures 2 and 3 show examples of weak and robust circadian activity rhythmicity.

**Fatigue**

The 30-item Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) was used to measure fatigue [33], which resulted in five subscales/factors: General, Physical, Emotional, Mental, and Vigor. Each subscale includes six items, and each item is rated on a 5-point scale indicating how true the statement was during the last week (0 = not at all, 4 = extremely). The sum of General, Physical, Emotional, and Mental subscale scores minus the Vigor subscale score generates a total score. Range of possible scores for each subscale is 0 to 24, and the range for total score is –24 to 96, with higher score indicating more severe fatigue, except for the Vigor subscale, where a larger score indicates less fatigue.

**Depressive symptoms**

Depressive symptoms were measured with the Center of Epidemiological Studies-Depression (CES-D) [34], a 20-item Likert scale of depressive symptoms based on the degree to which symptoms were experienced during the last week. This scale has been shown to have high reliability and validity in the assessment of depressive symptoms [34]. Since the CES-D reflects cognitive and affective symptoms rather than somatic symptoms of depression, it is highly recommended for use with patients with medical problems.

**Data analysis**

Descriptive statistics (mean, standard deviation, and standard error) were calculated for all outcomes at all three time points, and group differences (WBC vs matched-controls) were evaluated with t-tests and chi-square tests as appropriate.

A mixed model analysis was used to examine the changes in neuropsychological tests and total PAOF score from Baseline to Cycle-4 and 1-Year, with group and time included as fixed covariate effects. Baseline was the reference time point.
and the matched-control group was the reference group. A group-by-time interaction was tested; significance of the group-by-time term would indicate the changes from Baseline between the two groups were significantly different. A random intercept was included in each mixed model to account for subject-specific effects. Further post hoc tests were conducted using appropriate contrasts: between group differences at each time point, and/or within group changes between any two time points.

Finally, in order to explore predictors of changes in objective and subjective cognitive functioning in the WBC, a series of mixed models were fit with the neuropsychological composite or domain score, or the total PAOF score, as the repeated measures dependent variable, i.e., a vector comprising the Baseline, Cycle-4 chemotherapy, and 1-Year values of the outcome. The independent variables, assessed in separate models, included subjective cognitive functioning (total PAOF score) or objective cognitive functioning (composite score), sleep (PSQI, TST, WASO, %sleep and NAPTIME), fatigue, depressive symptoms, and the circadian activity rhythmicity (R-squared). Leveraging the availability of longitudinal predictors (i.e., sleep, fatigue etc), we included the independent variables as time-varying covariates in the mixed models with the tested predictor included as a random effect in each mixed model, thereby allowing for subject-specific slope terms for this particular predictor in the model. Time was modeled as a fixed (categorical) effect representing Baseline (reference), Cycle-4, and 1-Year. Since objective and subjective cognitive functioning were correlated with age and education, the age and education (with or without a college degree) were adjusted for these two variables as co-variates in all mixed models; additionally, since BMI was also correlated with total PAOF score, BMI was adjusted in all PAOF models. Thus, our marginal model can be written as

\[ Y_{ij} = \beta_0 + \beta X_{ij} + \beta_2 \text{covariates} + \text{error}, \]

where \( Y_{ij} \) and \( X_{ij} \) are the cognition outcome and predictor respectively for subject \( i \) at time \( j \) with the baseline time-point corresponds to \( j = 1 \), i.e., the reference; “covariates” refers to the covariates such as time, age, and education that were included in the model. Due to the inclusion of time-varying predictors, the coefficient \( \beta \) represents the (average) change in outcome (\( Y \)) per 1-unit increase in predictor \( X \), and thus can be interpreted in our study as the average change (from baseline) in cognition score corresponding to a 1-unit increase (from baseline) in the predictor (e.g., total sleep time). The adjusted regression coefficients (\( \beta \)-value)

---

**Fig. 3** Example of a robust CAR. This woman with BC showed a robust sleep-wake rhythm at baseline, indicated by clear contrast between daytime and nighttime activity. This patient’s rhythm remained overall stable and robust throughout chemotherapy. X-axis is clock time. Y-axis is log value. Black dots, log of activity scores calculated by the actigraphy. Blue line, best-fitting traditional cosine curve. Red line, extended cosine curve. Green line, in-bed time.
with standard errors and associated p-values of that model are presented.

All analyses were performed using version 9.3 of SAS (SAS Institute Inc. 2010).

**Results**

**Demographics and participant characteristics**

Demographics and disease characteristics are listed in Table 2. There were no significant differences between the two groups in age, BMI, race, education, marital status, household annual income, or baseline menopause status (all p’s > 0.16). There were also no significant differences in baseline levels of objective or subjective cognitive ability.

The trajectories of symptoms of sleep (subjective and objective), fatigue, depressive symptoms, and CAR over time were previously reported [19]. To briefly summarize, WBC spent more time napping and had more disrupted CARs and reported worse sleep quality, more fatigue, more depressive symptoms, and worse QOL than the matched-controls at baseline, cycle-4, and 1-Year. WBC also showed significantly worse sleep, increased fatigue, more depressive symptoms, and more disrupted CARs compared to their own baseline levels and to matched-controls at Cycle-4. At 1-year, these symptoms in the WBC returned to baseline levels but were still significantly worse than the matched-controls [19].

**Changes in objective measures of cognitive function over time**

**Composite score** The neuropsychological composite test results are shown in Fig. 4, with higher scores indicating better objective cognitive function. After adjusting for age and education, mixed model analysis for the composite score showed no significant group effect (p = 0.22) with post hoc analysis showing no significant differences between the two groups at baseline or at any of the three time points (all p > 0.14). There was a significant time effect for WBC (p = 0.015) with post hoc analysis showing that the neuropsychological composite score showed no change from Baseline to Cycle-4 (p = 0.330), but increased scores (i.e., improved scores) from Baseline to 1-Year (p = 0.004) and from Cycle-4 to 1-Year (p = 0.041). There was also a significant time effect for matched-controls (p < 0.0001) with post hoc analysis showing that the neuropsychological composite scores increased (i.e., improved) from Baseline to Cycle-4 (p = 0.001), from Baseline to 1-Year (p < 0.0001), and from Cycle-4 to 1-Year (p = 0.039). Similar results were found for Episodic Learning/ Memory and Executive Function (data not shown).

**Table 2** Demographic and disease characteristics of women with breast cancer and women with no cancer (matched-controls)

| Characteristics                        | Women with breast cancer (n = 69) | Matched-controls (n = 64) |
|----------------------------------------|----------------------------------|----------------------------|
| Age (years)                            | Mean (SD) 52.2 (9.5)             | 51.9 (9.3)                 |
| Range                                  | 31 – 80                          | 29 – 81                    |
| Body mass index (BMI, kg/m²)           | Mean (SD) 27.5 (7.4)             | 26.9 (8.5)                 |
| Range                                  | 19.3 – 61.9                      | 19.1 – 64.5                |
| Race [n (%)]                           | Caucasian 61 (88.4)              | 56 (87.5)                  |
|                                       | Non-Caucasian 8 (11.6)           | 8 (12.5)                   |
| Education [n (%)]                      | Below completed college 35 (50.7)| 23 (35.9)                  |
|                                       | Completed college and above 34 (49.3) | 41 (64.1)                |
| Marital status [n (%)]                 | Never married 3 (4.3)            | 7 (10.9)                   |
|                                       | Divorced/separated/widowed 18 (26.1)| 13 (20.3)                 |
|                                       | Married 48 (69.6)                | 44 (68.8)                  |
| Household annual income [n (%)]        | < $100,000 43 (62.3)             | 41 (64.1)                  |
|                                       | > $100,000 26 (37.7)             | 23 (35.9)                  |
| Baseline menopausal status [n (%)]     | pre-menopause 27 (40.9)          | 23 (37.7)                  |
|                                       | peri-menopause 7 (10.6)          | 8 (13.1)                   |
|                                       | post-menopause 27 (40.9)         | 22 (36.1)                  |
|                                       | hysterectomy 5 (7.6)             | 8 (13.1)                   |
| Not available                          | 3                                | 3                          |
| Cancer stage [n (%)]                   | Stage I 16 (23.5)                | -                          |
|                                       | Stage II 29 (42.7)               | -                          |
|                                       | Stage III 23 (33.8)              | -                          |
|                                       | Not available 1                  | -                          |
| Surgery type                           | Lumpectomy 33 (47.8)             | -                          |
|                                       | Mastectomy 30 (43.5)             | -                          |
|                                       | Double mastectomy 3 (4.3)        | -                          |
|                                       | No surgery before Chemotherapy 3 (4.3) | -                      |
| Chemotherapy regimen [n (%)]           | AC 12 (18.2)                     | -                          |
|                                       | AC + docetaxel 6 (9.1)           | -                          |
|                                       | AC + paclitaxel 34 (51.5)        | -                          |
|                                       | Other 14 (21.2)                  | -                          |
| Not available                          | 3                                | -                          |

There were no significant differences between the two groups in age, BMI, race, education, marital status, household annual income, and baseline menopause status (all p’s > 0.09). AC Doxorubicin + Cyclophosphamide
Changes in subjective measures of cognitive function over time

PAOF total scores are shown in Fig. 5, with higher scores indicating self-perception of worse functioning. After adjusting for variance attributable to age and education, mixed model analysis for the PAOF total score showed that the group effect was not significant \( (p = 0.052) \); post hoc analysis showed no difference between the groups at baseline \( (p = 0.79) \), but compared to matched-controls, WBC reported significantly higher total PAOF score at Cycle-4 \( (p = 0.0054) \) and 1-Year \( (p = 0.004) \) and from Cycle-4 to 1-Year \( (p = 0.041) \).

Matched controls (NC) scores increased (i.e., improved) from Baseline to Cycle-4 \( (p = 0.012) \) and 1-Year \( (p < 0.0001) \). There was no significant group effect \( (p = 0.22) \) or group-by-time interaction \( (p = 0.13) \). Age and education were controlled in the mixed models. NP Neuropsychological test battery. Baseline, before the start of chemotherapy; Cycle-4, at the end of cycle 4 chemotherapy; 1-Year, 1 year after the start of chemotherapy.

Predictors of objective and subjective cognitive functioning

As seen in Table 3, after adjusting for variance attributable to age, education, and time, mixed model results showed that the changes in the objective neuropsychological composite score were negatively associated with changes in total PAOF score, total PSQI score, and NAPTIME, and positively associated with changes in circadian activity rhythmicity (R-squared; all \( p \)-s < 0.05), indicating that a decrease in cognitive functioning (at follow-up compared to baseline) was predicted by changes resulting in less robust CARs, worsening self-assessment of cognitive ability, worsening sleep quality, and increases in nap time compared to baseline.

As seen in Table 4, after adjusting for variance attributable to age, education, BMI, and time, mixed model results showed that the changes in subjective assessment of cognitive function (total PAOF score) were negatively associated with changes in neuropsychological composite score, and positively associated with changes in total PSQI score, total MFSI-SF score, and total CES-D score, indicating that compared to baseline, worsening objective cognitive functioning, sleep, fatigue, and depressive symptoms were associated with worsening self-reported cognitive function.

WASO and %sleep were not significantly associated with changes in either objective or subjective cognitive function.
This report describes a novel prospective study which included comprehensive objective and subjective cognitive assessment and a pre- and post-chemotherapy design with a 1-Year follow-up [35], to examine the short and long-term effects of chemotherapy on objective and subjective cognitive functioning among women treated for breast cancer [35] compared to a matched-control group. Predictors

### Discussion

This report describes a novel prospective study which included comprehensive objective and subjective cognitive assessment and a pre- and post-chemotherapy design with a 1-Year follow-up [35], to examine the short and long-term effects of chemotherapy on objective and subjective cognitive functioning among women treated for breast cancer [35] compared to a matched-control group. Predictors
of cognitive change [2, 36, 37], specifically well-established and well-defined measures of objective and subjective sleep and circadian rhythmicity, were also examined. The results showed that declines in robustness of the CAR, sleep (specifically subjective reports of sleep quality and recorded time spent napping) from baseline to the end of cycle 4 and to 1-year later were consistently associated with declines in objective measures of cognitive function. Declines in objective measures of cognitive function, subjective sleep quality, fatigue, and depression from baseline to the end of cycle 4 and to 1-year later were consistently associated with declines in subjective reports of cognitive function. Changes in TST, WASO, and %sleep were not significantly associated with changes in either objective or subjective measures of cognitive function.

In WBC, objective neuropsychological testing showed no change in cognition at the end of cycle-4 chemotherapy compared to baseline, but there was an increase in performance scores from pre- and post-chemotherapy to one year later which is consistent with other findings [38]. On the other hand, matched-controls showed an increase in performance scores from baseline to the time point equivalent to the end of cycle-4, and continued to show increasing test performance at one year. The increases in performance scores seen in the matched-controls likely reflect practice effects, as is common with repeated testing due to increased task familiarity (even with use of alternate forms to avoid learning of specific content) [39]. The absence of improved test-performance with repeated testing among WBC from pre-chemotherapy to post-chemotherapy therefore requires explanation. Only one year later did they manifest some improvement in test performance. A failure to benefit from practice effects seen in these women may represent a form of learning deficit [40]. On the other hand, it is reasonable to consider that acute effects of chemotherapy might have contributed to poorer performance at Cycle-4, especially since the WBC increased their scores to those of the matched-controls at 1-Year. This type of pattern may suggest transient effects rather than the insidious decline more often observed in Alzheimer’s Disease [41].

In a study examining white matter integrity in patients with cancer and survivors, time since treatment was negatively associated with less white matter integrity in the survivor group, suggesting microstructural integrity deterioration over time [14]. That idea, along with our finding that the WBC showed no practice effect on their objective neuropsychological tests [41], adds additional support to the idea that the impact on cognition may be in the ability to gain new knowledge and learning. Our results also support the value of having a non-patient group comparison for repeated neuropsychological tests [41].

While there was no difference in reports of subjective cognitive function between the two groups at Baseline, the WBC reported significantly more subjective cognitive impairment at both Cycle-4 and 1-Year. They also reported significantly more impairment compared to their own baseline levels. A review by Hutchison et al. on differences between patient-reported and objectively measured cognitive disabilities found that only 8 of 24 studies identified a significant relationship between the two, and suggested that this phenomenon might be explained by the differences in measurement methods and in definitions of impairment.
Likewise, Bray et al. attributed a low rate of correlation between objective and subjective cognitive measures to an inadequate assessment of cognitive function in many of the questionnaires [43]. Ganz et al. found that correlations between objective and subject measures of cognitive function were domain specific [10].

Consistent with our second hypothesis, the strongest predictors of objective cognitive change were changes in robustness of the CAR, sleep, and fatigue, after covarying for age, education, and time. Similar findings were also reported in other studies, with changes in cognition following chemotherapy for breast cancer being associated with baseline fatigue, depression and functional well-being [44]. Depression and fatigue were found to account for brain activation differences which resulted in changes in cognitive function [6]. However, our study is unique in that we evaluated longitudinal effects, i.e., how changes in predictors impacted changes in cognition.

The present finding that the neuropsychological function was predicted by the robustness of the CAR is consistent with evidence that less robustness is predictive of cognitive decline in older adults [45] and associated with Alzheimer's Disease [46]. However, to our knowledge, this is the first study to report these results in patients with cancer.

Since this was an observational study, the results do not definitely establish that impairments in sleep and circadian synchronization cause declines in cognitive function. However, multiple studies have shown that experimentally induced sleep impairment [47] and circadian misalignment elicit impairments in cognitive function [48]. Conversely, interventions to promote sleep (e.g., cognitive behavioral treatment for insomnia; CBT-I) and circadian synchronization (e.g., bright light) have elicited improvements in cognitive function and fatigue or kept them from getting worse in breast cancer [49, 50]. Further research exploring the benefits of CBT-I and bright light is warranted for patients with breast cancer and other types of cancer.

The current study had several strengths. Both objective neuropsychological tests and subjective assessment were used to measure cognitive changes over time, a longitudinal design was employed with the last testing time point at one year after the start of chemotherapy, and the inclusion of a matched-control group. There are also some interpreted caveats that should be noted. Although selected carefully, some of the neuropsychological sub-tests used in the study may not have been sensitive enough to capture subtle cognitive changes induced by chemotherapy and this may have contributed to the inconsistencies between the neuropsychological test scores and self-reported cognitive complaints. On the other hand, the impact of such subtle cognitive changes on everyday functioning is likely minimal. A second caveat is that the 1-Year follow-up occurred one year after the start of chemotherapy; therefore, it may be possible that the findings might represent ongoing recovery at the 1-Year timepoint. The last caveat is that data were only collected in women with stage I-III breast cancer, so the conclusions cannot be extended to patients with other stages of breast cancer, with other types of cancer, or men.

In summary, chemotherapy-induced subjective complaints in neurocognitive functioning were reported by patients (compared to matched-controls) not only during chemotherapy, but even one year after treatment. On the other hand, there were no pre- to post-chemotherapy changes in objectively measured cognitive functioning, although there were improvements from both of those time-points to the 1-Year follow-up. The matched-controls, however, improved during all three intervals. One plausible explanation of this pattern is that chemotherapy may acutely diminish normative practice effects generally seen with repeated test exposures. Worsening objective cognitive function was predicted by increased disruption of CARs, increases in subjective complaints of neurocognitive functioning, decreases in sleep quality, and increases in time spent napping while worsening subjective reports of cognitive function were predicted by decreases in objective measures of neurocognitive functioning, and decreases in sleep quality, fatigue, and depression. Interventions targeting these predictors, such as light therapy for improving CARs,[51, 52] and fatigue [50], and cognitive behavioral therapy for insomnia for sleep [53], might benefit patients' cognitive function during and after chemotherapy.

**Code availability** Not applicable.

**Author contribution** Sonia Ancoli-Israel was the PI of the study and contributed to the study conception, design, material preparation, and writing and commenting on previous versions of the manuscript.

Lianqi Liu contributed to the study conception, design, and material preparation and wrote the first draft of the manuscript as well as commenting on all versions of the manuscript.

Loki Natarajan contributed to the study conception, design, material preparation, and writing and commenting on previous versions of the manuscript. Dr. Natarajan also performed the statistical analyses.

Michelle Rissling contributed to material preparation, data collection, and commenting on all versions of the manuscript.

Ariel Neikrug contributed to material preparation, data collection, and commenting on all versions of the manuscript.

Shawn Youngstedt contributed to writing and commenting on previous versions of the manuscript.

Paul Mills contributed to the study conception, design, material preparation, and writing and commenting on previous versions of the manuscript.

Georgia Sadler contributed to the study conception, design, material preparation, and writing and commenting on previous versions of the manuscript.

Joel Dimsdale contributed to the study conception, design, material preparation, and writing and commenting on previous versions of the manuscript.

Barbara Parker contributed to the study conception, design, material preparation, and writing and commenting on previous versions of the manuscript.
Barton Palmer contributed to the study conception, design, material preparation, and writing and commenting on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding This work was supported by NCI CA112035, UL1RR031980 (ACTRI) and the Department of Veterans Affairs Center of Excellence for Stress and Mental Health (CESAMH).

Declarations

Ethics approval All procedures performed in studies involving human participants were in accordance with the ethical standards of UCSD and with the 1964 Helsinki Declaration and its later amendments. The study was approved by the UCSD Office of IRB Administration and by the UC San Diego Moores Cancer Center’s Protocol Review and Monitoring Committee.

Consent to participate All participants provided written informed consent before participation.

Consent for publication Participants consented to publication of results which did not include the identity of any individual participant.

Conflict of interest SAI is a consultant for Eisai, Biogen, Idorsia, Merck, and Pear Therapeutics. The other authors have no relevant financial or non-financial interests to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Janelinsins MC, Kesler SR, Ahles TA, Morrow GR (2014) Prevalence, mechanisms, and management of cancer-related cognitive impairment. International Review of Psychiatry 26(1):102–113. https://doi.org/10.3109/09540261.2013.864260
2. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116(14):3348–3356. https://doi.org/10.1002/cncr.25098
3. Joly F, Lange M, Dos Santos M, Vaz-Luis I (1896) Di Meglio A (2019) Long-term fatigue and cognitive disorders in breast cancer survivors. Cancers 11(12)
4. van Dam FS, Boogerd W, Schagen SB, Muller MJ, Droogleever Fortuy ME, Ev W, Rodenhuis S (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. JNCI: Journal of the National Cancer Institute 90(3):210–218
5. Collins B, MacKenzie J, Tasca GA, Sherling C, Smith A (2013) Cognitive effects of chemotherapy in breast cancer patients: a dose–response study. Psycho-Oncology 22(7):1517–1527
6. Zunini RAL, Sherling C, Wallis N, Collins B, MacKenzie J, Bielajew C, Smith AM (2013) Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective FMRI study. Brain Imaging and Behavior 7(4):460–477
7. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg EK (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20(2):485–493
8. El-Agamy SE, Abdel-Aziz AK, Esmat A, Azab SS (2019) Chemotherapy and cognition: comprehensive review on doxorubicin-induced chemobrain. Cancer chemotherapy and pharmacology:1-14
9. Wefel JS, Schagen SB (2012) Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 12(3):267–275. https://doi.org/10.1007/s11910-012-0264-9
10. Ganz PA, Kwan L, Castellon SA, Oppenheim A, Bower JE, Silverman DH, Cole SW, Irwin MR, Ancoli-Israel S, Belin TR (2013) Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. JNCI: Journal of the National Cancer Institute 105(11):791–801
11. Schmidt ME, Wiskemann J, Steindorf K (2018) Quality of life, problems, and needs of disease-free breast cancer survivors 5 years after diagnosis. Qual Life Res 27(8):2077–2086
12. Feng Y, Wang YF, Zheng LJ, Shi Z, Huang W, Zhang LJ (2020) Network-level functional connectivity alterations in chemotherapy treated breast cancer patients: a longitudinal resting state functional MRI study. Cancer Imaging 20(1):1–13
13. Chen BT, Jin T, Patel SK, Ye N, Sun C-L, Ma H, Rockne RC, Root JC, Saykin AJ, Ahles TA (2018) Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat 172(2):363–370
14. Koppelman V, de Groot M, de Ruiter MB, Boogerd W, Seynaeve C, Vernooij MW, Niessen WJ, Schagen SB, Breteler MM (2014) Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. Hum Brain Mapp 35(3):889–899
15. Rogers-Sooder TS, Blackwell T, Yaffe K, Ancoli-Israel S, Redline S, Cauley JA, Ensrud KE, Fauld M, Barrett-Conner E, LeBlanc E (2018) Rest-activity rhythms and cognitive decline in older men: the osteoporotic fractures in men sleep study. J Am Geriatr Soc 66(11):2136–2143
16. Sultan A, Choudhary V, Parganiha A (2017) Worsening of rest-activity circadian rhythm and quality of life in female breast cancer patients along progression of chemotherapy cycles. Chronobiol Int 34(5):609–623. https://doi.org/10.1080/07420528.2017.1286501
17. Xu S, Thompson W, Ancoli-Israel S, Liu L, Palmer B, Natarajan L (2018) Cognition, quality-of-life, and symptom clusters in breast cancer: using Bayesian networks to elucidate complex relationships. Psychooncology 27(3):802–809. https://doi.org/10.1002/pon.4571
18. Carroll JE, Small BJ, Tometchik DB, Zhai W, Zhou X, Luta G, Ahles TA, Saykin AJ, Nudelman KN, Clapp JD (2019) Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotype. Cancer 125(24):4516–4524
19. Ancoli-Israel S, Liu L, Rissling M, Natarajan L, Neikrug AB, Palmer BW, Mills PJ, Parker BA, Sadler GR, Maglione J (2014) Sleep, fatigue, depression, and circadian activity rhythms in women with breast cancer before and after treatment: a 1-year longitudinal study. Support Care Cancer 22(9):2535–2545
20. Mormont M-C, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, Lellouch J, Misset J-L, Toutou Y, Lévi F (2000) Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6(8):3038–3045

21. Innominito PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchetti S, Coudert B, Iacobelli S, Genet D (2009) Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res 69(11):4700–4707

22. Cash E, Sephton SE, Chagpar AB, Spiegel D, Rebholz WN, Zimmarno LA, Tillie JM, Dhabhar FS (2015) Circadian disruption and biomarkers of tumor progression in breast cancer patients awaiting surgery. Brain Behav Immun 48:102–114. https://doi.org/10.1016/j.bbi.2015.02.017

23. Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonize studies of cognitive function in patients with cancer. The lancet oncology 12(7):703–708

24. Klem JP, Myers JS, Fabian CJ, Kimler BF, Khan QJ, Sereika SM, Stanton AL (2018) Cognitve functioning and quality of life following chemotherapy in pre-and peri-menopausal women with breast cancer. Support Care Cancer 26(2):575–583

25. Liu L, Rissling M, Neiruk A, Fiorentino L, Natarajan L, Faierman M, Sadler GR, Dimsdale JE, Mills PJ, Parker BA, Ancoli-Israel S (2013) Fatigue and circadian activity rhythms in breast cancer patients before and after chemotherapy: a controlled study. Fatigue: Biomedicine, Health & Behavior 1(1-2):12–26. https://doi.org/10.1080/21641846.2012.741782

26. Liu L, Fiorentino L, Rissling M, Natarajan L, Parker BA, Dimsdale JE, Mills PJ, Sadler GR, Ancoli-Israel S (2013) Decreased health-related quality of life in women with breast cancer is associated with poor sleep. Behav Sleep Med 11(3):189–206

27. Mayo SJ, Lustberg M, Dhillon MH, Nakamura ZM, Allen DH, Von Ah D, Janelensis CM, Chan A, Olson K, Tan CJ, Toh YL, Oh J, Grech L, Cheung YT, Subbiah IM, Petranovic D, D’Olimpio J, Gobbo M, Koepen S et al (2021) Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Support Care Cancer 29(6):2821–2840. https://doi.org/10.1007/s00520-020-05860-9

28. Rourke SB, Halman MH, Bassel C (1999) Neurocognitive complaints in HIV-infection and their relationship to depressive symptoms and neuropsychological functioning. J Clin Exp Neuropsychol 21(6):737–756

29. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28(2):193–213

30. Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP (2003) The role of actigraphy in the study of sleep and circadian rhythms. Sleep 26(3):342–392

31. Marler MR, Gehman P, Martin JL, Ancoli-Israel S (2006) The sigmoidally transformed cosine curve: a mathematical model for circadian rhythms with symmetric non-sinusoidal shapes. Stat Med 25(22):3893–3904

32. Savard J, Liu L, Natarajan L, Rissling MB, Neiruk AB, He F, Dimsdale JE, Mills PJ, Parker BA, Sadler GR, Ancoli-Israel S (2009) Breast cancer patients have progressively impaired sleep-wake activity rhythms during chemotherapy. Sleep 32(9):1155–1160. https://doi.org/10.1093/sleep/32.9.1155

33. Stein KD, Martin SC, Hann DM, Jacobsen PB (1998) A multidimensional measure of fatigue for use with cancer patients. Cancer Pract 6(3):143–152

34. Radloff LS (1977) The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1(3):385–401

35. Wagner LL, Gray RJ, Sparano JA, Whelan TJ, Garcia SF, Yanez B, Tevaarwerk AJ, Carlos RC, Albain KS, Olson JA Jr, Goetzi MP, Pritchard KJ, Hayes DF, Geyer CE, Dees EC, McCaskill-Stevens WJ, Minasian LM, Sledge GW Jr, Cella D (2020) Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemotherapy: results from TAILORx. J Clin Oncol 18(17):1875–1886. https://doi.org/10.1200/jco.19.01866

36. Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, Murlowwy TN, Schwartz GN, Kaufman PA (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28(29):4434–4440. https://doi.org/10.1200/JCO.2009.27.0827

37. Mandelblatts JS, Small BJ, Luta G, Hurria A, Jim H, McDonal BC, Graham D, Zhou X, Clapp J, Zhai W (2018) Cancer-related cognitive outcomes among older breast cancer survivors in the thinking and living with cancer study. J Clin Oncol 36(32):3211

38. Ono M, Ogilvie JM, Wilson JS, Green HJ, Chambers SK, Ownsworth T, Shum DH (2015) A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. Front Oncol 5:59

39. Lezak MD, Howieson DB, Bigle ED, Tranel D (2012) Neuropsychological assessment, 5th edn. Oxford University, New York

40. Jutten RJ, Grandoi F, Foldi NS, Sikkas SA, Jones RN, Choi SE, Lamar ML, Louden DK, Rich J, Tommet D (2020) Practice effects as a marker of cognitive performance and dementia risk: a literature review. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 12(1):e12055

41. Goldberg TE, Harvey PD, Wesnes KA, Snyder PJ, Schneider LS (2015) Practice effects due to serial cognitive assessment: implications for preclinical Alzheimer’s disease randomized controlled trials. Alzheimers Dement (Amst) 1(1):103–111. https://doi.org/10.1017/tjad.2014.11.003

42. Hutchinson AD, Hosking J, Kingendassie G, Mattede JS, Wilson C (2012) Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev 38(7):926–934

43. Bray VJ, Dhillon HM, Vardy JL (2018) Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment. J Cancer Surviv 12(4):537–559

44. Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G (2009) Predictors of cognitive decline after chemotherapy in breast cancer patients. Journal of the International Neuropsychological Society: JINS 15(6):951

45. Walsh C, Tranah G, Stone K, Blackwell T, Redline S, Paudel M, Ancoli-Israel S, Kramer JH, Yaffe K (2013) P3–149: Circadian activity rhythm patterns in nondemented older women and cognitive function 5 years later. Alzheimers Dement 9:P608–P608

46. van Someren EJ, Hagebeuk EE, Lijzenga C, Scheltens P, de Rooij SE, Jonker C, Pot A-M, Mirmiran M, Swaab DF (1996) Circadian rest—activity pattern disturbances in Alzheimer’s disease. Biol Psychiatry 40(4):259–270

47. Banks S, Dinges DF (2007) Behavioral and physiological consequences of sleep restriction. J Clin Sleep Med 3(5):519–528

48. Chellappa SL, Morris CJ, Scheer F (2019) Effects of circadian misalignment on cognition in chronic shift workers. Sci Rep 9:11649. https://doi.org/10.1038/s41598-018-36762-w

49. Matthews EE, Berger AM, Schmiege SJ, Cook PF, McCarthy MS, Moore CM, Aloia MS (2014) Cognitive behavioral therapy
for insomnia outcomes in women after primary breast cancer treatment: a randomized, controlled trial. Oncol Nurs Forum 3

50. Ancoli-Israel S, Rissling M, Neikrug A, Trofimenko V, Natarajan L, Parker BA, Lawton S, Desan P, Liu L (2012) Light treatment prevents fatigue in women undergoing chemotherapy for breast cancer. Support Care Cancer 20(6):1211–1219

51. Neikrug AB, Rissling M, Trofimenko V, Liu L, Natarajan L, Lawton S, Parker BA, Ancoli-Israel S (2012) Bright light therapy protects women from circadian rhythm desynchronization during chemotherapy for breast cancer. Behav Sleep Med 10(3):202–216. https://doi.org/10.1080/15402002.2011.634940

52. Jeste N, Liu L, Rissling M, Trofimenko V, Natarajan L, Parker BA, Ancoli-Israel S (2013) Prevention of quality-of-life deterioration with light therapy is associated with changes in fatigue in women with breast cancer undergoing chemotherapy. Qual Life Res 22(6):1239–1244

53. Fiorentino L, McQuaid JR, Liu L, Natarajan L, He F, Cornejo M, Lawton S, Parker BA, Sadler GR, Ancoli-Israel S (2010) Individual cognitive behavioral therapy for insomnia in breast cancer survivors: a randomized controlled crossover pilot study. Nature and science of sleep 2:1

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.